{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:37:02Z","timestamp":1789940222598,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clml.2015.03.018","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T21:32:10Z","timestamp":1428269530000},"page":"496-505.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion"],"prefix":"10.1016","volume":"15","author":[{"given":"Meenakshi","family":"Mehrotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto N.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Muddasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal M.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.03.018_bib1","first-page":"44","article-title":"Primary myelofibrosis","author":"Thiele","year":"2008"},{"key":"10.1016\/j.clml.2015.03.018_bib2","first-page":"159","article-title":"Myeloproliferative neoplasia: a review of clinical criteria and treatment","volume":"70","author":"Koopmans","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.clml.2015.03.018_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.6061\/clinics\/2013(03)OA09","article-title":"Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome","volume":"68","author":"Benites","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.clml.2015.03.018_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cancergen.2013.02.002","article-title":"Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes","volume":"206","author":"Hauck","year":"2013","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clml.2015.03.018_bib5","doi-asserted-by":"crossref","first-page":"e59791","DOI":"10.1371\/journal.pone.0059791","article-title":"JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis","volume":"8","author":"Barosi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2015.03.018_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2009.10.014","article-title":"Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations","volume":"197","author":"Millecker","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.clml.2015.03.018_bib7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","article-title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.03.018_bib8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.2174\/187152012803529727","article-title":"JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?","volume":"12","author":"Santos","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.clml.2015.03.018_bib9","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.03.018_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1517\/14728222.2012.662956","article-title":"Targeting JAK2 in the therapy of myeloproliferative neoplasms","volume":"16","author":"Reddy","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.clml.2015.03.018_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJMe1115119","article-title":"Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms","volume":"366","author":"Tefferi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.03.018_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.018_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1399-0004.2004.00322.x","article-title":"Microarray-based comparative genomic hybridization and its applications in human genetics","volume":"66","author":"Oostlander","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.clml.2015.03.018_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.drudis.2008.06.007","article-title":"The array CGH and its clinical applications","volume":"13","author":"Shinawi","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clml.2015.03.018_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2353\/jmoldx.2009.080037","article-title":"Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia","volume":"11","author":"Sargent","year":"2009","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2015.03.018_bib16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2353\/jmoldx.2006.060029","article-title":"Application of array-based comparative genomic hybridization to clinical diagnostics","volume":"8","author":"Bejjani","year":"2006","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2015.03.018_bib17","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.03.018_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clml.2011.03.031","article-title":"Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia","volume":"11","author":"Ma","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2015.03.018_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2012-0209-OA","article-title":"Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms","volume":"137","author":"Lu","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2015.03.018_bib20","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.018_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1309\/AJCPS6C8EVYCQNRM","article-title":"Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms","volume":"135","author":"Dunlap","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2015.03.018_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood.V91.1.231","article-title":"Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies","volume":"91","author":"La Starza","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.018_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/gcc.20885","article-title":"13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia","volume":"50","author":"Dal Bo","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2015.03.018_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2141.2001.02754.x","article-title":"Fluorescence in situ hybridization analysis of 25 cases of idiopathic myelofibrosis and two cases of secondary myelofibrosis: monoallelic loss of RB1, D13S319 and D13S25 loci associated with cytogenetic deletion and translocation involving 13q14","volume":"113","author":"Sinclair","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.03.018_bib25","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3324\/haematol.2010.039768","article-title":"Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia","volume":"96","author":"Gunnarsson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.03.018_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2403242","article-title":"Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis","volume":"18","author":"Cuneo","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.03.018_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cancergencyto.2006.02.001","article-title":"Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis","volume":"168","author":"Athanasiadou","year":"2006","journal-title":"Cancer Genet Cytogenet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:51Z","timestamp":1761870411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S2152265015001354"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.03.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}